Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1618 Trials   78436 News 


«12...1516171819202122232425...910911»
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Journal, Real-world evidence:  A Real-world Study on Tezepelumab Effectiveness in Severe Asthma Focusing on Small Airway Dysfunction. (Pubmed Central) -  Apr 27, 2025   
    Tezepelumab significantly reduced exacerbations and improved asthma control, positively impacting respiratory parameters and small airway function in patients with SAD. These findings support SAD as a treatable trait, highlighting the importance of integrating advanced diagnostic tools, such as body plethysmography and FOT, into routine clinical practice.
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen, Delytact (teserpaturev) / Daiichi Sankyo
    Review, Journal:  Advances in the Drug Development and Quality Evaluation Principles of Oncolytic Herpes Simplex Virus. (Pubmed Central) -  Apr 27, 2025   
    Although much progress has been achieved, there is still much work to be done regarding the optimization of treatment protocols and the quality control of oncolytic virus drugs. The approval of various oncolytic virus therapies underlines their clinical relevance, safety, and efficacy, thereby paving the way for further research aimed at overcoming the existing limitations and enhancing patient responses.
  • ||||||||||  Review, Journal:  New Therapeutic Challenges in Pediatric Gastroenterology: A Narrative Review. (Pubmed Central) -  Apr 27, 2025   
    In EoE, biologics like dupilumab, cendakimab, dectrekumab (IL-13 inhibitors), and mepolizumab, reslizumab, and benralizumab (IL-5/IL-5R inhibitors) show varying efficacy, while thymic stromal lymphopoietin (TSLP) inhibitors like tezepelumab are also being investigated...For IBD, biologics like vedolizumab, ustekinumab, and risankizumab, as well as small molecules like tofacitinib, etrasimod, and upadacitinib, are emerging treatments...Personalized therapy, integrating precision medicine, therapeutic drug monitoring, and lifestyle changes, is increasingly guiding pediatric IBD management. This narrative review explores recent breakthroughs in treating CeD, EoE, IBD, and AIH, with a focus on pediatric studies when available, and discusses the growing role of proteomics in advancing personalized gastroenterological care.
  • ||||||||||  Prolia (denosumab) / Amgen, zoledronic acid / Generic mfg.
    Review, Journal:  Mitigating the Risk of Skeletal Events in Metastatic Renal Cell Carcinoma. (Pubmed Central) -  Apr 27, 2025   
    PATIENT SUMMARY: Bone metastases in patients with kidney cancer can cause severe complications such as pain, fractures, and other serious issues, reducing quality of life and survival. Treatment involves a combination of therapies, including medications, targeted radiation, surgery, and immunotherapy, tailored to each patient to manage symptoms and improve outcomes.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Retrospective data, Review, Journal:  Anti-osteoporosis medication in patients with posterior spine fusion: a systematic review and meta-analysis. (Pubmed Central) -  Apr 27, 2025   
    Moreover, bisphosphonates can be utilized in patients with contraindications to teriparatide since the former prevents osteoporosis-related complications compared to controls, resulting in improved PROs. Further studies are warranted to evaluate the potential effects of denosumab and romosozumab.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Biomarker, Journal:  Plasma SuPAR and therapeutic response to erenumab in migraine: a REFORM study. (Pubmed Central) -  Apr 27, 2025   
    P4
    Plasma suPAR concentrations remained stable, even among participants with aura. These findings suggest that systemic low-grade inflammation, as measured by suPAR, does not influence treatment efficacy.
  • ||||||||||  omecamtiv mecarbil (AMG 423) / Amgen, Servier
    Journal:  Estimation of Active Tension in Cardiac Microtissues by Solving a PDE-Constrained Optimization Problem. (Pubmed Central) -  Apr 27, 2025   
    Next, we employed the procedure to evaluate active tension changes in drug escalation studies of the inotropes omecamtiv mecarbil and Bay K8644...The computational framework presented here allows for spatiotemporal estimation of active tension in cardiac microtissues based on optical measurements. In the future, such methodologies might develop into valuable tools in drug development protocols.
  • ||||||||||  Tecentriq (atezolizumab) / Roche
    Journal:  Large vessel vasculitis associated with atezolizumab. (Pubmed Central) -  Apr 27, 2025   
    Although large vessel vasculitis was reported in one patient who had received both atezolizumab and pegfilgrastim, our patient represents the first instance of large vessel vasculitis associated with atezolizumab alone. Discontinuation of atezolizumab and tapered glucocorticoid therapy resulted in clinical and radiographic resolution.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Navigating Thyroid Eye Disease: From Diagnosis to Management (Room 205) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_2971;    
    The medical management has been dominated by steroids but recently an IGF1 receptor blocker, teprotumumab, has significantly changed the field...2. TED medical management requires endocrinology-type skills yet is done by ophthalmologists.Corollary - endocrinologists would be ideal partners to ophthalmologists in guiding medical management of TED, if they would familiarize themselves with TED evaluation.
  • ||||||||||  Prolia (denosumab) / Amgen
    Iodine-Induced Thyrotoxicosis Leading to Severe Osteoporosis: A Case Report (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_2738;    
    She also started denosumab but was lost to follow-up...Kelp and similar supplements can exceed the recommended iodine intake of 1,100 mcg/day, necessitating dietary education.This case highlights the difficulty of managing iodine-induced thyrotoxicosis, especially when unrecognized supplement intake is involved. Comprehensive care should include dietary counseling and, when needed, psychiatric evaluation to address behavioral patterns contributing to excessive supplement use and related health risks.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    From Hashimoto's Thyroiditis to Graves' Disease: Autoimmune Thyroid Disease, a Dynamic Spectrum (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_2717;    
    This case is a cardinal reminder of this, and it documents the rare but possible phenomenon of transitioning from a diagnosis of HT to GD. Furthermore, it underscores the importance of the close monitoring of thyroid studies and antibody profiles in patients with an autoimmune thyroid disease.
  • ||||||||||  5-fluorouracil / Generic mfg.
    A Case of Idiopathic Arginine Vasopressin Deficiency Diagnosed Following Worsening of Thirst, Polydipsia, and Polyuria During Chemotherapy (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_2350;    
    Chemotherapy with FOLFOX + Pmab (Fluorouracil, Oxaliplatin, Panitumumab) was initiated in August 2023...Administration of DDAVP 60 ?g/day at bedtime resolved nocturnal polyuria, with urine osmolality improving to 525-746 mOsm/kg H2O.[Discussion]The patient had mild polydipsia and polyuria prior to chemotherapy, but these symptoms worsened after its initiation, leading to the diagnosis of AVP-D...Autoimmune mechanisms, such as lymphocytic infundibulo-neurohypophysitis, are thought to contribute to idiopathic AVP-D. We have previously reported that over 30% of idiopathic AVP-D cases are positive for anti-rabphilin-3A antibodies.As for the worsening of diabetes insipidus symptoms after chemotherapy, possible explanations include the effects of steroids used in chemotherapy, undetectable micro-metastases in the hypothalamo-hypophyseal region, or newly induced pituitary dysfunction caused by chemotherapy.
  • ||||||||||  Prolia (denosumab) / Amgen
    Rebound Hypercalcemia Months After Denosumab Administration (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_2339;    
    This leads to decreased bone resorption and a reduction in calcium mobilization into the circulation (2). Rebound hypercalcemia after the discontinuation of denosumab is an infrequent effect that is due to the high bone turn over that occurs in the period without treatment.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    "Strengthening Bones, Supporting Lives: Romosozumab in Osteoporosis Management for Marfan Syndrome" (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_2338;    
    Given the severity of her osteoporosis, our patient completed a 12-month course of therapy without any significant side effects and was found to have clinically significant improvement in her axial bone mineral density.CONCLUSIONTo our knowledge, there are no case reports on use of Romosozumab in the MFS population with osteoporosis. This case report highlights this therapy as a possible effective therapeutic intervention but also recognizes the need for ongoing research to establish standard and effective treatment guidelines for management of osteoporosis in MFS.
  • ||||||||||  Prolia (denosumab) / Amgen
    The Complexities of Osteoporosis in Spinal Cord Injury: Diagnosis, Management, and Multidisciplinary Care (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_2337;    
    Teriparatide and abaloparatide, though effective in increasing BMD, may have lower efficacy in SCI.A multidisciplinary approach is essential to management OP in SCI including nutrition and physical therapy modalities that attenuate BMD loss. General physicians should maintain a high index of suspicion for OP in SCI patients, as early recognition and intervention are key to preventing fractures and improving patient outcomes.
  • ||||||||||  Prolia (denosumab) / Amgen
    Effectiveness of an Online Osteoporosis Training Course for Physicians of Various Specialties: Implementation Results and Clinical Benefits (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_2319;    
    Treatment: Pharmacological interventions (bisphosphonates, denosumab, anabolic agents) and non-pharmacological approaches (nutrition, physical activity, fall prevention)...The results demonstrate that a structured, multidisciplinary approach to osteoporosis education can significantly improve physicians' competence and patient outcomes. The integration of general concepts, diagnostics, and treatment strategies along with practical case-based learning, ensures that participants not only understand the theoretical aspects but also gain the confidence to apply this knowledge in real-world settings.
  • ||||||||||  Prolia (denosumab) / Amgen
    Persistent Hypercalcemia and Parathyromatosis: Insights from a Rare Decade-Long Clinical Case (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_2309;    
    Intermittent zoledronic acid infusions and hydration therapy offered temporary relief but did not address the underlying hyperparathyroidism, leaving her at continued risk for hypercalcemia-related complications.Overall, this case contributes to the growing body of literature on parathyromatosis and emphasizes the significant challenges in its management...The need for a multidisciplinary approach, involving surgeons, endocrinologists, and radiologists, is crucial for optimizing outcomes. Future research should focus on improving detection and treatment methods for disseminated parathyroid tissue and refining surgical approaches to prevent parathyromatosis after initial parathyroidectomy.
  • ||||||||||  Prolia (denosumab) / Amgen, Cresemba (isavuconazonium sulfate) / Astellas, Basilea
    Hypercalcemia in a Case of Coccidiomycosis (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_1789;    
    Multiple mechanisms of hypercalcemia in coccidioidomycosis have been proposed, including granuloma formation and increased PTHrP expression. As such, various treatment strategies - including hydration, bisphosphonate therapy, corticosteroids, may be employed, particularly in cases of refractory hypercalcemia despite antifungal therapy.
  • ||||||||||  Prolia (denosumab) / Amgen
    Hypercalcemia with Elevated 1,25-Dihydroxyvitamin D in a Patient with Disseminated Coccidiomycosis (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_1783;    
    The patient completed a total 7-day course of prednisone therapy followed by a 5-day taper, and serum adjusted calcium remained normal at his 1-month follow-up without necessitation for further treatment. This case suggests that hypercalcemia in disseminated coccidiomycosis may have a more complex pathophysiology than previously thought and further investigation is needed to fully understand this condition.
  • ||||||||||  Remicade (infliximab) / J&J, Prolia (denosumab) / Amgen
    Hypercalcemia Secondary to Silicone-Implant Induced Granulomatous Disease (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_1775;    
    A year later, he presented with hematuria and CoCA of 14.9 mg/dL and was treated with IV fluids, calcitonin, prednisone, and zoledronic acid with minimal improvement in CoCA to 12 mg/dl...During a third admission for flank pain and hypercalcemia with CoCA of 13.8 mg/dl in a one-year timeframe; the patient was treated with IV fluids and denosumab without improvement in calcium levels...After discussion with the Dermatology team, a single dose of TNF-alpha inhibitor infliximab 5mg/kg was given with improvement in CoCa to 11 mg/dL at discharge and a decrease in serum 1,25-di-hydroxy vitamin D from 79pg/mL to 41pg/dL...The efficacy of bisphosphonates and other anti-resorptive agents may be limited given the underlying mechanism of excessive 1,25 di-hydroxy vitamin D-induced hypercalcemia. If necessary, TNF alpha inhibitors may offer a potential therapeutic option by reducing inflammation within the granulomas thereby lowering the excessive production of active 1,25-di-hydroxy vitamin D.
  • ||||||||||  Prolia (denosumab) / Amgen
    Hypercalcemia of Malignancy in Pregnancy (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_1772;    
    Production of RANKL by neoplastic T-cells is the most significant mechanism but PTH-rP production can also contribute. This patient had a mildly elevated PTH-rP which may be normal in pregnancy due to its production by the placenta and breasts.